Lead Product(s): Nolasiban
Therapeutic Area: Obstetrics/Gynecology (Womens Health)
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Yuyuan BioScience Technology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 13, 2020
This sublicense agreement aims to develop and commercialize nolasiban for improving clinical pregnancy and live birth rates in women undergoing embryo transfer following in-vitro fertilization (IVF).